Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Oncogene ; 36(31): 4508-4515, 2017 08.
Article in English | MEDLINE | ID: mdl-28368402

ABSTRACT

Melanoma is a dangerous form of skin cancer derived from the malignant transformation of melanocytes. The transcription factor SOX2 is not expressed in melanocytes, however, it has been shown to be differentially expressed between benign nevi and malignant melanomas and to be essential for melanoma stem cell maintenance and expansion in vitro and in xenograft models. By using a mouse model in which BRafV600E mutation cooperates with Pten loss to induce the development of metastatic melanoma, we investigated if Sox2 is required during the process of melanomagenesis, melanoma growth and metastasis and in the acquisition of resistance to BRAF inhibitors (BRAFi) treatments. We found that deletion of Sox2 specifically in Pten null and BRafV600E-expressing melanocytes did not prevent tumor formation and did not modify the temporal kinetics of melanoma occurrence compared to Sox2 wt mice. In addition, tumor growth was similar between Sox2 wt and Sox2 deleted (del) melanomas. By querying publicly available databases, we did not find statistically significant differences in SOX2 expression levels between benign nevi and melanomas, and analysis on two melanoma patient cohorts confirmed that Sox2 levels did not significantly change between primary and metastatic melanomas. Melanoma cell lines derived from both Sox2 genotypes showed a similar sensitivity to vemurafenib treatment and the same ability to develop vemurafenib resistance in long-term cultures. Development of vemurafenib resistance was not dependent on SOX2 expression also in human melanoma cell lines in vitro. Our findings exclude an oncogenic function for Sox2 during melanoma development and do not support a role for this transcription factor in the acquisition of resistance to BRAFi treatments.


Subject(s)
Melanoma/etiology , SOXB1 Transcription Factors/physiology , Animals , Cell Line, Tumor , Drug Resistance, Neoplasm , Humans , Indoles/therapeutic use , Melanoma/drug therapy , Melanoma/pathology , Melanoma/secondary , Mice , PTEN Phosphohydrolase/genetics , PTEN Phosphohydrolase/physiology , Proto-Oncogene Proteins B-raf/antagonists & inhibitors , Proto-Oncogene Proteins B-raf/genetics , Proto-Oncogene Proteins B-raf/physiology , Sulfonamides/therapeutic use , Vemurafenib
2.
Oncogene ; 33(12): 1601-8, 2014 Mar 20.
Article in English | MEDLINE | ID: mdl-23584479

ABSTRACT

Mutant p53 proteins are expressed at high frequency in human tumors and are associated with poor clinical prognosis and resistance to chemotherapeutic treatments. Here we show that mutant p53 proteins downregulate micro-RNA (miR)-223 expression in breast and colon cancer cell lines. Mutant p53 binds the miR-223 promoter and reduces its transcriptional activity. This requires the transcriptional repressor ZEB-1. We found that miR-223 exogenous expression sensitizes breast and colon cancer cell lines expressing mutant p53 to treatment with DNA-damaging drugs. Among the putative miR-223 targets, we focused on stathmin-1 (STMN-1), an oncoprotein known to confer resistance to chemotherapeutic drugs associated with poor clinical prognosis. Mutant p53 silencing or miR-223 exogenous expression lowers the levels of STMN-1 and knockdown of STMN-1 by small interfering RNA increases cell death of mutant p53-expressing cell lines. On the basis of these findings, we propose that one of the pathways affected by mutant p53 to increase cellular resistance to chemotherapeutic agents involves miR-223 downregulation and the consequent upregulation of STMN-1.


Subject(s)
Down-Regulation/genetics , Drug Resistance, Neoplasm/genetics , MicroRNAs/genetics , Mutation , Tumor Suppressor Protein p53/genetics , Tumor Suppressor Protein p53/metabolism , Antineoplastic Agents/pharmacology , Cell Line, Tumor , Down-Regulation/drug effects , Gene Expression Regulation, Neoplastic/drug effects , Humans , Stathmin/genetics
3.
Cell Death Differ ; 20(11): 1498-509, 2013 Nov.
Article in English | MEDLINE | ID: mdl-23933816

ABSTRACT

Werner syndrome (WS) results from dysfunction of the WRN protein, and is associated with premature aging and early death. Here we report that loss of WRN function elicits accumulation of the Yes-associated protein (YAP protein), a major effector of the Hippo tumor suppressor pathway, both experimentally and in WS-derived fibroblasts. YAP upregulation correlates with slower cell proliferation and accelerated senescence, which are partially mediated by the formation of a complex between YAP and the PML protein, whose activity promotes p53 activation. The ATM kinase is necessary for YAP and PML accumulation in WRN-depleted cells. Notably, the depletion of either YAP or PML partially impairs the induction of senescence following WRN loss. Altogether, our findings reveal that loss of WRN activity triggers the activation of an ATM-YAP-PML-p53 axis, thereby accelerating cellular senescence. The latter has features of SASP (senescence-associated secretory phenotype), whose protumorigenic properties are potentiated by YAP, PML and p53 depletion.


Subject(s)
Ataxia Telangiectasia Mutated Proteins/metabolism , Exodeoxyribonucleases/metabolism , Nuclear Proteins/metabolism , RecQ Helicases/metabolism , Transcription Factors/metabolism , Tumor Suppressor Protein p53/metabolism , Tumor Suppressor Proteins/metabolism , Cell Cycle Proteins , Cellular Senescence/physiology , Exodeoxyribonucleases/deficiency , HCT116 Cells , HEK293 Cells , Humans , MCF-7 Cells , Promyelocytic Leukemia Protein , RecQ Helicases/deficiency , Signal Transduction , Transfection , Werner Syndrome Helicase , p38 Mitogen-Activated Protein Kinases/metabolism
4.
Cell Death Dis ; 3: e423, 2012 Nov 15.
Article in English | MEDLINE | ID: mdl-23152059

ABSTRACT

Micro RNAs (miRs) are small non-coding RNAs aberrantly expressed in human tumors. Here, we aim to identify miRs whose deregulated expression leads to the activation of oncogenic pathways in human gastric cancers (GCs). Thirty nine out of 123 tumoral and matched uninvolved peritumoral gastric specimens from three independent European subsets of patients were analyzed for the expression of 851 human miRs using Agilent Platform. The remaining 84 samples were used to validate miRs differentially expressed between tumoral and matched peritumoral specimens by qPCR. miR-204 falls into a group of eight miRs differentially expressed between tumoral and peritumoral samples. Downregulation of miR-204 has prognostic value and correlates with increased staining of Bcl-2 protein in tumoral specimens. Ectopic expression of miR-204 inhibited colony forming ability, migration and tumor engraftment of GC cells. miR-204 targeted Bcl-2 messenger RNA and increased responsiveness of GC cells to 5-fluorouracil and oxaliplatin treatment. Ectopic expression of Bcl-2 protein counteracted miR-204 pro-apoptotic activity in response to 5-fluorouracil. Altogether, these findings suggest that modulation of aberrant expression of miR-204, which in turn releases oncogenic Bcl-2 protein activity might hold promise for preventive and therapeutic strategies of GC.


Subject(s)
MicroRNAs/genetics , Proto-Oncogene Proteins c-bcl-2/genetics , Stomach Neoplasms/genetics , Animals , Antineoplastic Agents/pharmacology , Cell Line, Tumor , Fluorouracil/pharmacology , Gene Expression Regulation, Neoplastic/drug effects , Humans , Mice , Mice, Nude , MicroRNAs/metabolism , Organoplatinum Compounds/pharmacology , Oxaliplatin , Proto-Oncogene Proteins c-bcl-2/metabolism , Stomach Neoplasms/drug therapy , Stomach Neoplasms/metabolism , Up-Regulation
5.
Cell Death Differ ; 19(6): 1038-48, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22193543

ABSTRACT

p53 mutations have profound effects on non-small-cell lung cancer (NSCLC) resistance to chemotherapeutic treatments. Mutant p53 proteins are usually expressed at high levels in tumors, where they exert oncogenic functions. Here we show that p53R175H, a hotspot p53 mutant, induces microRNA (miRNA)-128-2 expression. Mutant p53 binds to the putative promoter of miR128-2 host gene, ARPP21, determining a concomitant induction of ARPP21 mRNA and miR-128-2. miR-128-2 expression in lung cancer cells inhibits apoptosis and confers increased resistance to cisplatin, doxorubicin and 5-fluorouracyl treatments. At the molecular level, miR-128-2 post-transcriptionally targets E2F5 and leads to the abrogation of its repressive activity on p21(waf1) transcription. p21(waf1) protein localizes to the cytoplasmic compartment, where it exerts an anti-apoptotic effect by preventing pro-caspase-3 cleavage. This study emphasizes miRNA-128-2 role as a master regulator in NSCLC chemoresistance.


Subject(s)
E2F5 Transcription Factor/metabolism , MicroRNAs/metabolism , Tumor Suppressor Protein p53/metabolism , Apoptosis/drug effects , Carcinoma, Non-Small-Cell Lung/metabolism , Carcinoma, Non-Small-Cell Lung/pathology , Cell Line, Tumor , Cisplatin/pharmacology , Cyclin-Dependent Kinase Inhibitor p21/genetics , Cyclin-Dependent Kinase Inhibitor p21/metabolism , Doxorubicin/pharmacology , Drug Resistance, Neoplasm/drug effects , Fluorouracil/pharmacology , Humans , Lung Neoplasms/metabolism , Lung Neoplasms/pathology , Phosphoproteins/genetics , Phosphoproteins/metabolism , Promoter Regions, Genetic , RNA, Messenger/metabolism , Transcription, Genetic , Tumor Suppressor Protein p53/genetics
6.
Oncogene ; 26(15): 2212-9, 2007 Apr 02.
Article in English | MEDLINE | ID: mdl-17401430

ABSTRACT

Inactivation of tumor-suppressor genes is one of the key hallmarks of a tumor. Unlike other tumor-suppressor genes, p53 is inactivated by missense mutations in half of all human cancers. It has become increasingly clear that the resulting mutant p53 proteins do not represent only the mere loss of wild-type p53 tumor suppressor activity, but gain new oncogenic properties favoring the insurgence, the maintenance, the spreading and the chemoresistance of malignant tumors. The actual challenge is the fine deciphering of the molecular mechanisms underlying the gain of function of mutant p53 proteins. In this review, we will focus mainly on the transcriptional activity of mutant p53 proteins as one of the potential molecular mechanisms. To date, the related knowledge is still quite scarce and many of the raised questions of this review are yet unanswered.


Subject(s)
Neoplasms/genetics , Oncogenes , Transcription Factors/genetics , Transcription Factors/metabolism , Tumor Suppressor Protein p53/genetics , Tumor Suppressor Protein p53/metabolism , Humans , Mutation
7.
J Biol Chem ; 276(43): 40225-33, 2001 Oct 26.
Article in English | MEDLINE | ID: mdl-11502745

ABSTRACT

In vitro addition of stem cell factor (SCF) to c-kit-expressing A(1)-A(4) spermatogonia from prepuberal mice stimulates their progression into the mitotic cell cycle and significantly reduces apoptosis in these cells. SCF addition results in a transient activation of extracellular signal-regulated kinases (Erk)1/2 as well as of phosphatidylinositol 3-kinase (PI3K)-dependent Akt kinase. These events are followed by a rapid re-distribution of cyclin D3, which becomes predominantly nuclear, whereas its total cellular amount does not change. Nuclear accumulation of cyclin D3 is coupled to transient activation of the associated kinase activity, assayed using the retinoblastoma protein (Rb) as a substrate. These events were followed by a transient accumulation of cyclin E, stimulation of the associated histone H1-kinase activity, a delayed accumulation of cyclin A2, and Rb hyper-phosphorylation. All the events associated with SCF-induced cell cycle progression are inhibited by the addition of either a PI3K inhibitor or a mitogen-activated protein-kinase kinase (MEK) inhibitor, indicating that both MEK and PI3K are essential for c-kit-mediated proliferative response. On the contrary, the anti-apoptotic effect of SCF is not influenced by the separate addition of either MEK or PI3K inhibitors. Thus, SCF effects on mitogenesis and survival in c-kit expressing spermatogonia rely on different signal transduction pathways.


Subject(s)
Mitogen-Activated Protein Kinases/metabolism , Mitogens/pharmacology , Spermatogonia/cytology , Spermatogonia/drug effects , Stem Cell Factor/pharmacology , Animals , Apoptosis/drug effects , Cell Division , Cells, Cultured , Cyclin A/metabolism , Cyclin D3 , Cyclins/metabolism , DNA Fragmentation/drug effects , G1 Phase , Male , Mice , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinase 3 , Mitogen-Activated Protein Kinase Kinases/antagonists & inhibitors , Mitogen-Activated Protein Kinase Kinases/metabolism , Phosphatidylinositol 3-Kinases/metabolism , Phosphoinositide-3 Kinase Inhibitors , Protein Transport , Proto-Oncogene Proteins c-kit/biosynthesis , S Phase , Signal Transduction
8.
FEBS Lett ; 426(1): 62-6, 1998 Apr 10.
Article in English | MEDLINE | ID: mdl-9598979

ABSTRACT

The first complete amino acid sequence of a flavin-containing polyamine oxidase was solved by a combined approach of nucleotide and peptide sequence analysis. A cDNA of 1737 bp, isolated from maize seedlings by reverse transcription-polymerase chain reaction and rapid amplification of cDNA ends strategies, was cloned and its sequence determined. This cDNA contains information for a polypeptide chain of 500 amino acids. Its amino-terminal sequence shows the typical features of secretion signal peptides. The primary structure of the mature protein was independently confirmed by extensive amino acid sequencing. Structural relationships with flavin-containing monoamine oxidases are also discussed.


Subject(s)
Oxidoreductases Acting on CH-NH Group Donors/chemistry , Zea mays/enzymology , Amino Acid Sequence , Base Sequence , DNA, Complementary/genetics , Molecular Sequence Data , Monoamine Oxidase/chemistry , Oxidoreductases Acting on CH-NH Group Donors/genetics , Plant Proteins/chemistry , Plant Proteins/genetics , Sequence Alignment , Sequence Homology, Amino Acid , Zea mays/genetics , Polyamine Oxidase
SELECTION OF CITATIONS
SEARCH DETAIL
...